Cancer BiologybioRxivPreprint
EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer
Justine J. Jacobi, Kristine M. Wadosky, Neha Jaiswal…·David W. Goodrich
This study shows that EZH2 influences the evolution of aggressive prostate cancer subtypes but is not essential for neuroendocrine prostate cancer development.